PSY14 Observational study of ferric carboxymaltose (FCM) in france (oncofer study; interim analysis)  by Toledano, A. et al.
A112 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
PSY9  
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Horsham, PA, USA  
OBJECTIVES: Psoriasis is a chronic, immune-mediated, inflammatory skin 
disease that negatively impacts patients’ health-related quality-of-life. Biologic 
medications have been developed and approved for the condition in recent years 
that have greatly improved patients’ care; however, little is known about their 
comparative efficacy. Our research objective was to synthesize and compare the 
efficacy of two of these new biologic treatments, ustekinumab and adalimumab. 
METHODS: A literature review was conducted of randomized, controlled trials 
investigating the efficacy of ustekinumab (45 mg or 90 mg) and adalimumab 
(40mg) according to their approved FDA labels. As no head-to-head trials existed 
at the time of the study, a Bayesian network meta-analysis allowing for indirect 
comparisons was conducted on the ordered probit scale to evaluate comparative 
efficacy at a common week-12 time point based on the Psoriasis Area and 
Severity Index (PASI) 50, 75, 90, and 100 and the Physician’s Global Assessment 
(PGA) 0/1. The primary analysis was based on the intent-to-treat populations, 
and sensitivity analysis was conducted using the ustekinumab dose appropriate 
for patients’ body weight per the product label. RESULTS: Seven clinical trials 
representing over 4,000 patients were included in the meta-analysis. The meta-
analysis showed that PASI 50, 75, 90, and 100 response rates at week 12 were 
76%, 55%, 29%, and 10% for adalimumab; 89%, 73%, 47%, and 20% for 
ustekinumab 45 mg; and 91%, 76%, 51%, and 24% for ustekinumab 90 mg, 
respectively. PGA 0/1 response rates at week 12 were 58%, 64%, and 69% for 
adalimumab, ustekinumab 45 mg, and ustekinumab 90 mg, respectively. Weight-
based sensitivity analysis showed similar results between adalimumab and 
ustekinumab but higher efficacy for ustekinumab 45 mg in pts ≤100kg compared 
with ustekinumab 90 mg in pts >100kg per the label. CONCLUSIONS: This 
network meta-analysis provides additional information about the comparative 
effectiveness of ustekinumab and adalimumab in treatment of moderate-to-
severe PsO.  
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OBJECTIVES: The capsaicin 8% patch (QUTENZATM) is licensed for the treatment 
of peripheral neuropathic pain in non-diabetic adults. The purpose of  
this observational study was to determine if levels of effectiveness observed  
in clinical trials are translated into routine clinical practice, and to determine 
how this novel treatment is being used more generally by practicing physicians 
so that real-world cost effectiveness can be determined. METHODS: This 
observational study of routine practice (ASCEND) is being carried out using an 
online, electronic data capture platform for the case report forms that includes 
translation into multiple languages. Following treatment, at least 12 months’ 
follow-up is planned for each patient in this ongoing study. Demographic, 
clinical, process and patient-reported outcome parameters are reported. Pain is 
evaluated using the Numeric Pain Rating Scale (NPRS). RESULTS: A total of 166 
patients from 31 hospital sites in six European countries have been enrolled  
and treated with capsaicin 8% patch. Of these 59% are female with an  
overall mean age of 58.7 (sd 14.5) years. The reported indications include post-
operative and/or post-traumatic neuropathic pain (n 67; 43.2%) and post-herpetic 
neuralgia (31; 20.0%). Baseline mean pain score was 6.57 (sd 1.98) units.  
Pain improved by an average of 1.8 and 2.3 units on the NPRS at weeks two and 
eight, respectively (paired samples comparison p<0.001 at both time points). A 
total of 56% of enumerable subjects (N=100) were classified as responders to 
treatment (≥30% improvement in pain at the Week 8 assessment). On average, 
1.5 (sem 0.06) patches were used per treatment. CONCLUSIONS: When used in 
routine clinical practice, the degree of pain relief evident when using the 
capsaicin 8% patch was greater than the levels seen in randomised trials. 
Interestingly, this was achieved with a reduced number of patches, suggesting 
current cost-effectiveness estimates based on clinical trial data may be 
conservative.  
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OBJECTIVES: Undertake a meta-analysis of all randomized controlled trials 
(performed in China and other Countries) comparing effective and safety of 
ultrasonic scalpel (UAS) with conventional surgery for thyroidectomy. 
METHODS: A comprehensive search for published RCTs published in major 
medical database (PubMed, Embase, Elsevier, Wanfang and CNKI) was performed 
from January 2003 to November 2012; Reviews of each study were conducted and 
data were extracted.Outcome measures analyzed included operation time, 
intraoperative blood loss, overall drainage volume, length of stay and post-
operative complication rates. RESULTS: Data were retrieved from 26 RCTs(16 
from China, 10 from other countries) describing 3011 patients In most cases 
conventional vessel ligation and tight were used as a conventional method. The 
results of the meta-analysis demonstrated significant improvement of 
perioperative outcomes with the use of UAS instead of conventional surgical 
instrumentation. Operative time was significantly reduced from a mean of 84.6 
min to 61.7(WMD: -21.66 minutes; 95% CI: -22.61, -20.71) intraoperative blood loss 
was decreased from a mean of 61.4 ml to 31.6 ml (WMD: -23.58 mL; 95% CI: -
24.33,-22.83),length of stay was shorten from a mean of 5.8 to 4.8 days (WMD: -
0.8 day; 95% CI: -0.86, -0.72) , overall drainage volume was reduced from a mean 
of 56.9 ml to 37.4(WMD: -21.28 mL; 95% CI: -22.15, -20.41) in the patients 
underwent thyroidectomy with UAS. It also showed that the patients who were 
treated with UAS presented more favorable results in incidence of post-operative 
complications (OR: 0.54, 95% CI: 0.36, 0.81). CONCLUSIONS: Ultrasonic scalpel 
showed significant advantages over conventional methods in the thyroidectomy, 
including shortened operation time, shortened length of stay, reduced 
intraoperative blood loss and shortened overall drainage volume. Besides, it can 
also decrease the post-operative complication risks.  
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OBJECTIVES: The 1998 NHLBI Obesity Guidelines state “extremely obese persons 
often do not benefit from more conservative treatments for WL.” This post-hoc 
analysis explores the use of PHEN/TPM ER, a pharmacologic adjunct to lifestyle 
modifications, to impact WL across BMI ranges, including extreme obesity. 
METHODS: Data from two double-blind, placebo-controlled Phase 3 studies 
(CONQUER [BMI ≥27 to ≤45kg/m2], EQUIP [BMI ≥35kg/m2]) were pooled and 
subjects stratified by baseline BMI (kg/m2; <30, ≥30-<35, ≥35-<40, ≥40-<45, ≥45) 
and by randomized dose over 56 weeks (ITT-LOCF). Subjects were randomized to 
placebo (n=1477), PHEN 3.75mg/TPM ER 23mg (3.75/23; n=234), PHEN 7.5mg/TPM 
ER 46mg (7.5/46; n=488), or PHEN 15mg/TPM ER 92mg (15/92; n=1479). All subjects 
received the same lifestyle intervention. RESULTS: At baseline, mean weight was 
107.4 kg and mean BMI was 38.4 kg/m2. At week 56, least-squares mean percent 
WL was -1.5%, -4.7%, -8.2%, and -10.4% for placebo, 3.75/23, 7.5/46, and 15/92, 
respectively (P<.0001 versus placebo). Similar dose trends were seen when 
subjects were stratified by baseline BMI for placebo, 3.75/23, 7.5/46, and 15/92, 
respectively: BMI <30, -1.1%, dose not included in CONQUER, -9.1%, and -9.1%; 
BMI ≥30-<35, -1.8%, -10.3%, -8.0%, and -10.4%; BMI ≥35-<40, -1.8%, -5.5%, -8.8%, 
and -10.2%; BMI ≥40-<45, -1.9%, -4.4%, -8.3%, and -11.5%; and BMI ≥45, -1.3%,  
-5.5%, -8.8%, and -11.0% (P<0.005 versus placebo, all comparisons with 7.5/46 and 
15/92). Similar WL trends were observed with mean absolute WL (P<0.005 versus 
placebo, all comparisons with 7.5/46 and 15/92). Common adverse events were 
constipation, dry mouth, and paraesthesia. CONCLUSIONS: PHEN/TPM ER was 
associated with significant WL versus placebo across all BMI categories, with 
dose proportional percent WL increases across BMI categories within each 
treatment arm. We conclude that significant WL is possible across a wide range 
of BMIs, including extreme obesity, with PHEN/TPM ER use.  
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OBJECTIVES: This French multicenter observational study aims to describe 
clinical practice Ferric carboxymaltose (FCM) use in patients with hematological 
malignancies or solid tumors. METHODS: Two cohorts of patients (1:1)  
are enrolled. Cohort 1 (retrospective): patients treated in 2010 with any 
intravenous iron (IV) or red blood cell transfusion if no IV iron; Cohort 2 
(prospective): patients treated with FCM after July 1st 2011. Patient 
characteristics were collected for a period of 3 months pre and post intervention. 
Outcomes of the first 100 patients are described below. RESULTS: Fifty patients 
were analyzed in each cohort (mean age, 62 and 66 y.; solid tumors, 84% and 
100%; metastatic, 61% and 63% for Cohorts 1 and 2, respectively). In Cohort 1, 16 
patients received intravenous iron (iron sucrose (IS)) and 34 were transfused. The 
mean total iron dose was 706 mg for IS in cohort 1 and 960 mg for FCM in cohort 
2; the mean number of infusions was 3.8 and 1.8 for IS and FCM respectively. In 
cohort 2, 69% of the administrations were done at home. In patients receiving 
FCM without erythropoietin stimulating agents (ESA), mean Hb (g/dL) increased 
from 10.9 to 12.1, from baseline to Month 3. ESA use was 44% in cohort 1 vs 22% 
in cohort 2 during observational period. No serious adverse events related to IS 
or FCM were observed. CONCLUSIONS: FCM was well tolerated and effective in 
treating iron deficiency anemia. FCM was mostly given at home with fewer 
infusions required compared to IS. Interim results to be confirmed by the final 
analysis.  
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OBJECTIVES: Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune 
condition characterized by increased platelet destruction and suboptimal 
